CareDx to Participate in Upcoming June 2026 Investor Conferences
CareDx, Inc. announced its participation in two upcoming investor conferences in June 2026. The company will present at the Jefferies 2026 Global Healthcare Conference on June 3rd and hold a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on June 8th. Live and archived webcasts of both events will be available on CareDx's investor relations website.
CareDx plans June talks at Jefferies and Goldman Sachs healthcare events
CareDx, a precision medicine company focused on transplant patients, announced its participation in two upcoming investor conferences in June 2026. The company will present at the Jefferies 2026 Global Healthcare Conference and hold a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference. Webcasts of these events will be available on CareDx's investor relations website.
CareDx director Arthur Torres sells $214,675 in company stock By Investing.com
CareDx director Arthur Torres sold 10,570 shares of the company's common stock for approximately $214,675. The sales, which occurred on May 14 and May 15, 2026, leave Mr. Torres with 38,665 shares. Despite the sell-off, InvestingPro analysis suggests CareDx is undervalued, while recent financial reports show strong Q1 2026 results and an acquisition deal, leading BTIG to raise its price target.
CareDx (CDNA) director sells 10,570 shares in open-market trades
CareDx, Inc. director Arthur A. Torres sold a total of 10,570 shares of common stock in open-market transactions on May 14 and May 15, 2026, for approximately $214,676. The sales were executed at weighted average prices of $20.9735 and $19.8917 per share, respectively. Following these transactions, Arthur A. Torres directly holds 38,665 shares of CareDx common stock.
Insider Sell Alert: Arthur Torres Sells Shares of CareDx Inc (CDNA)
Arthur Torres, a Director at CareDx Inc (CDNA), sold 10,570 shares of the company on May 15, 2026. This transaction leaves him with 38,665 shares. CareDx Inc's stock was trading at $20.31, deemed fairly valued compared to its GF Value of $20.87.
CareDx director Arthur Torres sells $214,675 in company stock
CareDx director Arthur A. Torres sold 10,570 shares of the company's common stock for approximately $214,675 in two transactions on May 14 and 15, 2026. Following these sales, Torres directly holds 38,665 shares. The sales occurred as the stock trades up 27% over the past six months, despite the company reporting strong Q1 2026 financial results and announcing the acquisition of Naveris.
ETFs Investing in CareDx, Inc. Stocks
This article lists various Exchange Traded Funds (ETFs) that hold CareDx, Inc. stocks, providing detailed financial information for each. The data includes market value, weight of CareDx in the fund, issuer, management style, focus, expense ratio, assets under management (AUM), price, change percentage, relative volume, and 3-year NAV total return. The ETFs listed range across different investment styles and focuses, from active genomic revolution funds to passive small-cap and broader healthcare funds.
CareDx Lawsuit Resolution Refocuses Attention On Valuation And Growth Prospects
CareDx (NasdaqGM:CDNA) has seen a long-standing qui tam lawsuit dismissed, following a previous closure of a DOJ investigation without findings of wrongdoing. This resolution removes a significant legal overhang, allowing investors to refocus on the company's valuation, growth prospects in transplant diagnostics, and market execution. The stock is currently trading below analyst targets and Simply Wall St's estimated fair value, signaling a potential valuation gap.
Rule 144 notice and recent sale by insider (CDNA)
CareDx, Inc. (CDNA) insider Arthur Torres has filed a Rule 144 notice to sell 6,484 restricted common shares with an effective date of June 14, 2025. Additionally, the filing reports a recent sale of 4,086 common shares on May 14, 2026, for total proceeds of $85,697.72. The notice indicates a routine insider transaction with neutral impact and sentiment.
[144] CareDx, Inc. SEC Filing
This SEC filing for CareDx, Inc. (CDNA) is a Form 144, indicating a notice of proposed sale of restricted securities by an affiliate. The filing details include the issuer (CareDx, Inc.), the type of securities (Common Stock), the broker (Morgan Stanley Smith Barney LLC), and the acquisition details of the securities to be sold.
How Investors Are Reacting To CareDx (CDNA) Profit Return, Higher 2026 Outlook And New Shelf Registration
CareDx (CDNA) reported a return to profitability in Q1 2026 with net income of US$2.81 million and raised its full-year 2026 revenue outlook to between US$447 million and US$465 million. The company also filed an omnibus shelf registration, indicating plans for flexible future growth funding. Investors are weighing these positive developments against ongoing risks related to potential Medicare and LCD changes that could impact reimbursement rates.
How Investors Are Reacting To CareDx (CDNA) Profit Return, Higher 2026 Outlook And New Shelf Registration
CareDx (CDNA) reported a profit return in Q1 2026 with US$117.7 million in revenue and US$2.81 million in net income, reversing a prior year loss. The company raised its full-year 2026 revenue outlook to US$447-465 million and filed an omnibus shelf registration, signaling improved performance and future growth funding flexibility. This development strengthens confidence in CareDx's ability to grow despite evolving reimbursement rules, though potential Medicare and LCD changes remain a risk.
CareDx Announces Dismissal of 2021 Qui Tam Suit
CareDx, Inc. (Nasdaq: CDNA) announced the dismissal of a qui tam action filed against the company in 2021. The United States District Court for the Eastern District of New York dismissed the matter on April 23, 2026, with no associated monetary payment. This dismissal follows a request from the qui tam plaintiff and concurrence from the Department of Justice, which had previously concluded its investigation into CareDx without finding wrongdoing.
Earnings Preview: CareDx to Report Financial Results Post-market on April 28
CareDx is scheduled to report its financial results after the market closes on April 28. Investors will be keen to see if the company's performance meets expectations and what guidance it provides for the upcoming period. This report will be a key indicator of the company's financial health and future outlook.
Technical Reactions to CDNA Trends in Macro Strategies
This article from Stock Traders Daily provides a technical analysis of Caredx Inc. (NASDAQ: CDNA), indicating a near-term neutral sentiment amidst mid and long-term strength. It outlines three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis, support, and resistance levels. The report highlights an exceptional short setup with a high risk-reward ratio, targeting a 16.5% downside.
Insider Sell: Jeffrey Novack Sells 2,688 Shares of CareDx Inc (CDNA)
Jeffrey Novack, Secretary and General Counsel at CareDx Inc (CDNA), sold 2,688 shares of the company on May 5, 2026, bringing his total ownership to 113,924 shares. This transaction is part of a trend of insider selling at CareDx, with 15 insider sells and no buys over the past year. As of the sale date, CareDx stock was trading at $20.68, considered fairly valued against its GF Value of $20.55.
Insider Sell: Jeffrey Novack Sells 2,688 Shares of CareDx Inc (CDNA)
Jeffrey Novack, Secretary and General Counsel at CareDx Inc (CDNA), sold 2,688 shares of the company on May 5, 2026, reducing his total holdings to 113,924 shares. This transaction is part of a pattern of insider selling at CareDx, with 15 insider sells and no buys over the past year. As of the sale date, CareDx's stock was trading at $20.68, which is considered fairly valued according to its GF Value of $20.55.
CareDx (NASDAQ: CDNA) counsel's 2,688-share sale under 10b5-1
Jeffrey Adam Novack, Secretary and General Counsel of CareDx, sold 2,688 shares of the company's common stock at a weighted average price of $20.6775 per share on May 5, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on September 4, 2025. Following the sale, Novack directly owns 113,924 shares of CareDx common stock.
Insider Sell: Jeffrey Novack Sells 2,688 Shares of CareDx Inc (C
Jeffrey Novack, Secretary and General Counsel at CareDx Inc (CDNA), sold 2,688 shares of the company on May 5, 2026, reducing his total holdings to 113,924 shares. This transaction is part of a trend over the last year where insiders at CareDx Inc have made 15 sales and no purchases. The stock was trading at $20.68, which is considered fairly valued according to its GF Value.
[144] CareDx, Inc. SEC Filing
This article reports on a Form 144 SEC filing by CareDx, Inc. (CDNA), detailing a proposed sale of securities. The filing indicates a "Neutral" filing impact and sentiment, outlining the filer and issuer information, securities to be sold (2,688 common shares with an aggregate market value of $56,340.48), and the acquisition details of these restricted stock units. The document also includes required disclosures about past securities sales and a signature certifying no knowledge of undisclosed material adverse information.
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 1, 2026
CareDx, Inc. announced inducement grants to 23 new employees on April 30, 2026. These grants consist of 63,856 restricted stock units (RSUs) in aggregate, awarded under the company's 2019 and 2025 Inducement Equity Incentive Plans, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with a 25% vesting on the first anniversary and subsequent quarterly vesting thereafter, contingent on continuous employment.
CareDx (CDNA) General Counsel has 2,873 shares withheld to cover RSU taxes
CareDx, Inc. reported that its Secretary and General Counsel, Jeffrey Adam Novack, had 2,873 shares of common stock withheld by the company to cover tax obligations arising from the vesting of restricted stock units. This transaction occurred on May 1, 2026, with shares valued at $21.50 each. After this event, Novack directly holds 116,612 shares, clarifying that it was a compensation-related tax withholding and not a market sale or purchase.
How Investors Are Reacting To CareDx (CDNA) Profitability Milestone And Higher 2026 Revenue Guidance
CareDx, Inc. (CDNA) reported a significant shift to profitability in Q1 2026 with net income of US$2.81 million and raised its full-year revenue guidance to US$447–US$465 million, indicating improved operating performance. This move to profitability and increased revenue guidance is strengthening investor confidence, especially considering the company's transplant diagnostics business model, despite ongoing concerns about reimbursement policies and product concentration risk. The company's recent universal shelf registration also provides financial flexibility for future growth initiatives.
CareDx Announces First Quarter 2026 Financial Results
CareDx reported strong first-quarter 2026 financial results, with revenue increasing by 39% year-over-year to $118 million, driven by growth in testing services and patient and digital solutions. The company also raised its full-year 2026 revenue guidance to $447 million to $465 million and adjusted EBITDA guidance to $43 million to $57 million. Key business highlights included the divestiture of the Lab Products business, advancement of the AlloHeme clinical program, and the launch of VANTx™, an AI-powered clinical data platform.
How Investors Are Reacting To CareDx (CDNA) Profitability Milestone And Higher 2026 Revenue Guidance
CareDx (CDNA) has reported positive first-quarter 2026 results, achieving profitability with net income of US$2.81 million and raising its full-year revenue guidance to US$447–US$465 million. This shift to profitability and optimistic revenue forecasts are strengthening investor confidence, though ongoing concerns persist regarding Medicare reimbursement policies and product concentration risk. The company's recent universal shelf registration provides financial flexibility for future growth initiatives.
CareDx (NASDAQ:CDNA) Upgraded to Strong-Buy at Wall Street Zen
Wall Street Zen has upgraded CareDx (CDNA) to a "strong-buy" rating. This upgrade follows CareDx's recent quarterly earnings, which surpassed analyst expectations with an EPS of $0.34 against an expected $0.11 and revenue of $117.7 million, a 39.3% year-over-year increase. Despite the positive earnings, the company still reports negative net margins and return on equity, and analyst ratings on the stock remain mixed.
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CareDx Inc. has announced inducement grants in accordance with Nasdaq Listing Rule 5635(c)(4). This news comes from Quantisnow, a platform providing real-time market data to retail investors. The article also highlights recent analyst ratings and SEC filings related to CareDx.
CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CareDx, Inc. announced the award of inducement grants to 22 new employees on April 30, 2026. These grants consist of 63,896 shares of common stock in restricted stock units (RSUs). The RSUs will vest over four years, with 25% vesting on the first anniversary of each employee's vesting commencement date, and 1/16th vesting every three months thereafter, subject to continued service.
Analysts Offer Insights on Healthcare Companies: Janux Therapeutics Inc (JANX), Stryker (SYK) and CareDx (CDNA)
Three analysts have provided bullish insights on healthcare companies Janux Therapeutics Inc (JANX), Stryker (SYK), and CareDx (CDNA). Guggenheim maintained a Buy rating on Janux Therapeutics, RBC Capital reiterated a Buy on Stryker, and BTIG reaffirmed a Buy rating on CareDx. The reports include price targets and analyst success rates for each recommendation.
CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing
CareDx, Inc. announced a definitive agreement to acquire Naveris, a precision oncology diagnostics company specializing in viral-mediated cancer MRD surveillance testing. The acquisition, valued at $160 million upfront with an additional $100 million based on revenue milestones, is expected to extend CareDx's precision medicine strategy into oncology. Naveris's NavDx® test, which generated $34 million in unaudited revenue in 2025, is projected to grow 30-40% annually for the next three years and is anticipated to be neutral to CareDx's FY2026 Adjusted EBITDA guidance.
CareDx expands into cancer testing with $260M Naveris buy
CareDx, a precision medicine company specializing in transplant monitoring, is entering the oncology market through its acquisition of Naveris for up to $260 million. The deal includes an upfront payment of $160 million and an additional $100 million based on revenue milestones. This acquisition brings Naveris' liquid biopsy platform, NavDx, which detects HPV-driven cancers, into CareDx's portfolio, marking its first commercial cancer diagnostic.
CareDx Earnings Call: Growth Accelerates Amid Bold Pivot
CareDx Inc. (CDNA) reported strong Q1 2026 earnings, with total revenue up 39% year-over-year to $118 million, driven by its testing and digital businesses. The company raised its full-year 2026 revenue guidance, reflecting confidence in its growth trajectory after divesting its Lab Products business and acquiring Navaris to enter the oncology MRD market. While facing potential reimbursement changes and high operating costs, CareDx's strategic pivot toward higher-growth areas and a fortified balance sheet paint an encouraging outlook.
CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing
CareDx (Nasdaq: CDNA) has announced its agreement to acquire Naveris, a commercial-stage precision oncology diagnostics company, for an upfront cash consideration of $160 million, with potential additional payments up to $100 million based on revenue milestones. This acquisition extends CareDx’s precision medicine testing services into specialty oncology, focusing on viral-mediated cancers with Naveris' Medicare-reimbursed NavDx® test. Naveris reported $34 million in unaudited revenue in 2025, with an estimated growth of 30-40% annually for the next three years, and the transaction is expected to be neutral to CareDx’s FY2026 Adjusted EBITDA guidance.
CareDx to Acquire Oncology Diagnostics Company Naveris for $160 Million
CareDx Inc. is set to acquire Naveris, an oncology diagnostics company specializing in blood-based monitoring for viral-mediated cancers, for an upfront cash payment of $160 million, with potential for an additional $100 million based on future revenue milestones. This acquisition expands CareDx’s precision medicine offerings into oncology, leveraging Naveris's Medicare-reimbursed liquid biopsy platform for viral-mediated cancer detection and monitoring. The deal targets an estimated $4.5 billion market and is expected to enhance both companies' capabilities in transforming cancer care.
CareDx, Inc (NASDAQ:CDNA) Q1 2026 Earnings Call Transcript
CareDx, Inc. (NASDAQ:CDNA) reported strong Q1 2026 results, beating earnings expectations with an EPS of $0.34 against an anticipated $0.11. The company announced strategic portfolio changes, including the divestiture of its Lab Products business for $170 million and the acquisition of Navaris, a diagnostic platform for viral-mediated cancers, which is expected to significantly boost revenue and expand CareDx's market presence in specialty oncology. CareDx also raised its 2026 revenue guidance to $447 million-$465 million and adjusted EBITDA to $43 million-$57 million, demonstrating confidence in its growth strategy focused on precision medicine testing services and digital solutions.
CareDx (CDNA) Q1 2026: EPS $0.05 Beats -$0.03 Est; Revenue $118M
CareDx (CDNA) reported strong Q1 2026 results, with EPS of $0.05 significantly beating the -$0.03 estimate and revenue reaching $118 million, above the $104.03 million estimate. The company's testing services drove a 39% revenue growth and it raised its 2026 revenue and AEBITDA guidance. Despite these positive results, GuruFocus's GF Value framework indicates that the stock is currently 14.4% overvalued.
CareDx to Acquire Naveris, Expanding Oncology Diagnostics
CareDx (CDNA) is set to acquire Naveris, a circulating tumor DNA specialist, for up to $260 million, signaling an expansion into oncology diagnostics. This acquisition coincides with a new $100 million stock buyback program and strong Q1 2026 financial results for CareDx, which also plans to divest its Lab Products business to focus on high-margin transplant services and its new AI data platform. Despite an analyst rating of "Hold" for CDNA, its financial stability and strategic shifts are noted as positive, though profitability consistency and valuation remain areas of concern.
CareDx (NASDAQ: CDNA) boosts 2026 outlook, buys Naveris and launches $100M buyback
CareDx Inc. (NASDAQ: CDNA) has significantly boosted its 2026 financial outlook following a strong first quarter and the strategic acquisition of Naveris, a company specializing in viral-mediated cancer MRD surveillance. The deal, valued at $160 million upfront plus potential milestones, expands CareDx's precision medicine offerings. Additionally, the company announced a new $100 million stock buyback program, signaling confidence in its financial health and future growth.
CareDx Announces Agreement to Acquire Naveris, A Leader in Viral-Mediated Cancer MRD Surveillance Testing
CareDx, Inc. has announced a definitive agreement to acquire Naveris, a precision oncology diagnostics company specializing in viral-mediated cancer MRD surveillance testing. The acquisition, valued at an upfront cash consideration of $160 million with potential for an additional $100 million based on revenue milestones, is expected to extend CareDx’s Precision Medicine Testing Services into specialty oncology. Naveris's highly differentiated liquid biopsy platform, based on Tumor Tissue Modified Viral (TTMV®) DNA, generated $34 million in unaudited revenue in 2025 and is projected to grow 30-40% annually for the next three years.
Earnings Flash (CDNA) CareDx, Inc. Posts Q1 Adjusted EPS $0.34 per Share
CareDx, Inc. (CDNA) reported Q1 adjusted EPS of $0.34 per share and announced a full-year 2026 revenue forecast of $447 million to $465 million, surpassing FactSet's estimate of $432 million. The company is a precision medicine solutions provider focused on diagnostic solutions for transplant patients. CareDx also recently announced the divestiture of its lab products division for $170 million.
CareDx Announces First Quarter 2026 Financial Results
CareDx (Nasdaq: CDNA) reported strong first-quarter 2026 financial results with a 39% year-over-year revenue increase, reaching $118 million, driven by growth in testing services and patient and digital solutions. The company raised its full-year 2026 revenue guidance to $447 million to $465 million and adjusted EBITDA guidance to $43 million to $57 million, on the back of strategic divestitures and pipeline advancements. Key achievements include the planned divestiture of the Lab Products business and the launch of VANTx, an AI-powered clinical data platform.
CareDx: Q1 Earnings Snapshot
CareDx Inc. (CDNA) reported first-quarter earnings of $2.8 million, or 5 cents per share. Adjusted earnings were 34 cents per share, and the company posted revenue of $117.7 million. CareDx projects full-year revenue to be between $447 million and $465 million.
Caredx earnings up next: Can testing growth fuel turnaround?
Caredx Inc. is set to report first-quarter earnings, with analysts expecting a per-share loss of 6 cents on $104.12 million in revenue, following a stronger previous quarter. Investors will focus on the company's capital allocation from its recent divestiture, the momentum of its core testing business, and its path to sustainable profitability. The company's strategic shift towards high-growth testing services and digital solutions, supported by innovations, is key to its future earnings growth.
CareDx Q1 2026 earnings preview
This article provides a Q1 2026 earnings preview for CareDx. However, the content is empty, offering no specific details or financial forecasts for the upcoming earnings report.
Trading the Move, Not the Narrative: (CDNA) Edition
This article provides an AI-generated analysis for Caredx Inc. (NASDAQ: CDNA), highlighting weak near-term sentiment but strong mid and long-term signals. It outlines specific trading strategies, including long, breakout, and short positions, along with support and resistance levels across different time horizons. The analysis emphasizes an exceptional risk-reward short setup and offers real-time signals and personalized alerts for subscribers.
CareDx, Inc. (NASDAQ:CDNA) Given Average Rating of "Hold" by Brokerages
Eight brokerages have given CareDx, Inc. (NASDAQ:CDNA) an average "Hold" rating, with a consensus 12-month price target of $27.60. The company recently missed its EPS estimate but beat revenue expectations, reporting $0.12 EPS against an estimated $0.24, and $108.39 million in revenue. Institutional investors have significantly increased their stakes, while CEO John W. Hanna Jr. sold over 10,000 shares.
Assessing CareDx (CDNA) Valuation As Recent Share Price Swings Draw Investor Attention
CareDx (CDNA) has experienced recent share price volatility but shows significant long-term returns. While one narrative suggests the stock is 19.1% undervalued with a fair value of $24.80 due to expected growth, a discounted cash flow model by Simply Wall St indicates it might be slightly overvalued at $19.75, highlighting differing valuation perspectives. Investors should consider these mixed signals and conduct their own due diligence on the underlying data and assumptions.
CareDx (NASDAQ:CDNA) Upgraded at Wall Street Zen
Wall Street Zen has upgraded CareDx (NASDAQ:CDNA) from a "hold" to a "buy" rating, despite generally mixed analyst coverage which results in a consensus "Hold" rating and an average target price of $27.60. The company recently missed EPS expectations but exceeded revenue forecasts, with revenue up 25.2% year-over-year. Additionally, CareDx's CEO sold over 10,000 shares of the company's stock under a pre-arranged trading plan.
CareDx (NASDAQ: CDNA) boosts CFO/COO pay with new RSU and PRSU grants
CareDx (NASDAQ: CDNA) has increased the compensation for its Chief Financial Officer and Chief Operating Officer, Keith Kennedy, with new equity awards. These grants include 24,134 restricted stock units (RSUs) and 24,134 performance-based restricted stock units (PRSUs), acknowledging his expanded responsibilities. While his annual base salary of $613,000 and target bonus opportunity of 75% remain unchanged, the new equity awards provide additional incentive and are subject to vesting conditions tied to continued service and performance through 2027.
CareDx (NASDAQ: CDNA) CFO & COO granted 24,134 RSUs in equity award
CareDx, Inc. (NASDAQ: CDNA) CFO & COO Keith Kennedy was granted 24,134 Restricted Stock Units (RSUs) at a price of $0.00 per share, as detailed in a recent Form 4 filing. This award increases his direct holdings to 221,548 shares. The RSUs have a vesting schedule, with one-third vesting on April 6, 2027, and the remainder vesting quarterly over the subsequent eight quarters, provided his employment continues.
